GAVI's experience shows that innovation can defeat communicable diseases: innovative funding delivers sustainable resources, innovative partnerships reach common goals, and innovative technologies ensure equitable access to lifesaving advances. The Clinton Global Initiative applies a similar cutting-edge approach to global problem-solving, with global health as a top priority. GAVI's dialogue and CGI commitment to raise $30 million in private funds to prevent pneumococcal disease in developing countries is a strategic collaboration with clear results.
GAVI endeavors to secure $30 million from visionary philanthropists and other donors to support the Advance Market Commitment (AMC) pilot project to accelerate development and introduction of a pneumococcal vaccine formulated for developing countries and dispense priority vaccines where they are most needed.
Metrics:
The GAVI Fund's Immunize Every Child Campaign is a new initiative reaching out to leading individual philanthropists looking to achieve concrete results at global scale. The Campaign will identify partners to initially raise $30 million in innovation capital for the Advance Market Commitment pneumococcal vaccine and to support the introduction and distribution of the pneumo and other priority vaccines.
It is calculated that this $30 million investment, and additional public and private funds invested in the AMC, will help achieve long-term sustainable impact that prevents approximately 5.4 million deaths by 2030. Each additional million dollars adds to the 'acceleration capacity' of the AMC to deliver a new vaccine against pneumococcal disease to the world's children.
THE PROJECT
Problem: The World Health Organization estimates that up to one million children under five die each year from pneumococcal infections. These include pneumonia, which causes a child's lungs to fill with fluid; meningitis, an infection of the fluid surrounding the brain and spinal cord; and sepsis, an infection of the bloodstream. Nearly all of these 1 million children die in the world's poorest countries, GAVI supported countries.
This picture is growing more grim with each passing day. Pneumococcal infections are becoming more difficult to treat as bacteria become resistant to some of the most commonly used antibiotics. In addition, research shows that the incidence of pneumococcal disease will increase alongside the scourge of HIV/AIDS. A South African study found that children with HIV/AIDS are 20 to 40 times more likely than a healthy child to contract pneumococcal disease.
Solution: One of the major hurdles to improved global health addressed by GAVI is the lack of commercial incentive for vaccine producers to dedicate R&D resources to vaccines formulated for the developing world. The new concept known as an Advance Market Commitment (AMC) offers a powerful and cost-effective means to develop and introduce priority new vaccines against diseases that currently kill millions of children. This is how it works: the AMC commits to subsidize the future purchase (up to a pre-agreed price) of a priority vaccine when an appropriate vaccine is developed and as demanded by the poorest developing countries. Once the AMC is depleted, the market will be established, R and D costs recovered, and each participating firm will continue to supply the product at a pre-determined lower price that enables countries to sustain delivery of pneumococcal vaccines.
A $1.5 billion pilot AMC has been designed and launched for pneumococcal vaccines, with the expectation that an appropriate vaccine will be available in just three years. However, in the absence of an AMC pneumococcal vaccines will not reach the world's poorest countries before 2023, if then.
This pilot will support industry and governments in helping to prevent millions of unnecessary child deaths due to preventable pneumococcal disease. It will also enable stakeholders to quickly assess the AMC mechanism to determine how best to accelerate development, production scale-up, and introduction of other critically needed vaccines for diseases like rotavirus, malaria, tuberculosis, and HIV/AIDS.
The Advance Market Commitment is built around market incentives:
- Market entry: Open to all potential players - multinational and emerging, biotech companies as well as vaccine manufacturers.
- Competition: Designed to sustain 2-3 firms to encourage adequate capacity and price competition.
- Continued innovation: Designed to last 7-10 years to allow multiple products and to respond to country demand for products that best meet their needs.
The GAVI Alliance is a public-private partnership dedicated to saving children's lives and protecting people's health by increasing access to immunization in poor countries. More than 150 million children have been immunized and 2.3 million premature deaths prevented in 70 nations through GAVI support.
GAVI Campaign has initiated a partnerships effort to engage faith communities and member and service organizations. Opportunities to network and engage with these communities would be attractive to GAVI, as would the opportunity to cultivate relationships with other prospective funders and partners, including individual donors and philanthropists (at all levels) and corporations with the capacity for giving and/or consumer facing partnerships.
In addition to raising philanthropic funds to eradicate pneumococcal disease, The GAVI Fund's Immunize Every Child Campaign will work to raise public awareness of the devastating impact of pneumococcal disease and foster understanding and concerted action by decision makers at all levels. GAVI welcomes partners with skills and resources matching these tasks.
SEEKING: Financial Resources, Media/Marketing Opportunities
We are seeking service delivery and resource mobilization partnerships with capacity for advocacy and donor cultivation.
OFFERING: N/A
N/A
